Silo Pharma, Inc. (SILO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on June 1, 2026. The filing announces a corporate action regarding the Company's capital structure effective June 2, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure adjustment.
Material Changes
The Company announced a 1-for-15 reverse stock split of its issued and outstanding common stock. Key details include:
- Effective Time: 4:01 p.m. Eastern Time on June 2, 2026.
- Trading Resumption: Post-split trading begins on The Nasdaq Capital Market on June 3, 2026, under the symbol "SILO".
- Share Count Reduction: Issued and outstanding shares will decrease from approximately 16.267 million to approximately 1.084 million.
- Authorized Shares: A proportionate reduction will result in 6,666,667 authorized shares of common stock.
- Fractional Shares: Any fractional shares resulting from the split will be rounded up to the next higher whole share.
- CUSIP Update: The new CUSIP number will be 82711P 300.
- Equity Adjustments: Equitable adjustments will be made to shares issuable upon exercise of equity awards and warrants, as well as their exercise prices.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, or contingencies beyond the execution of the reverse split.
Investor Verification Checklist
- Confirm the new CUSIP number (82711P 300) with your broker to ensure proper trade execution.
- Verify the number of shares held post-split, noting that fractional shares are rounded up.
- Review the adjusted exercise prices and share counts for any outstanding options or warrants.
- Monitor trading activity on June 3, 2026, for the post-split share price.